On the recordJune 9, 2021
Transparency in the FDA's process of reviewing and approving potential therapies for ALS is also of the upmost importance.
Source
congress.govTransparency in the FDA's process of reviewing and approving potential therapies for ALS is also of the upmost importance.
Leahy stresses the importance of FDA transparency for ALS therapies.
Share
More from Patrick Leahy
I can say with absolute certainty that the proposed rules directly conflict with the legislation on a variety of matters, especially on provisions that limit access to the PTAB.
Congress was the original classification authority (OCA). It let that power essentially slip away to the Executive Branch.
People in the Trump administration who know nothing and care less about these programs are arbitrarily jeopardizing relations with a strategic partner in one of the most challenging regions of the world.